Volume | 325,578 |
|
|||||
News | - | ||||||
Day High | 22.30 | Low High |
|||||
Day Low | 21.69 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cassava Sciences Inc | SAVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
22.00 | 21.69 | 22.30 | 21.73 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,815 | 325,578 | $ 22.08 | $ 7,188,282 | - | 12.3202 - 32.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:02:29 | 8 | $ 22.02 | USD |
Cassava Sciences (SAVA) Options Flow Summary
Cassava Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
17.72M | 43.23M | - | 0 | -97.22M | -2.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cassava Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.01 | 22.30 | 19.47 | 20.53 | 792,860 | 1.05 | 5.00% |
1 Month | 20.26 | 26.6757 | 19.435 | 22.15 | 1,027,882 | 1.80 | 8.88% |
3 Months | 23.50 | 26.6757 | 18.18 | 21.92 | 749,221 | -1.44 | -6.13% |
6 Months | 18.38 | 32.10 | 17.45 | 23.40 | 988,310 | 3.68 | 20.02% |
1 Year | 21.96 | 32.10 | 12.3202 | 21.72 | 982,289 | 0.10 | 0.46% |
3 Years | 40.54 | 146.16 | 12.3202 | 49.62 | 2,375,116 | -18.48 | -45.58% |
5 Years | 1.12 | 146.16 | 1.00 | 34.20 | 2,783,522 | 20.94 | 1,869.64% |
Cassava Sciences Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. |